当前位置:首页 - 行情中心 - 特宝生物(688278) - 财务分析 - 利润表

特宝生物

(688278)

  

流通市值:211.93亿  总市值:211.93亿
流通股本:4.08亿   总股本:4.08亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入1,836,563,644.13797,791,349.653,695,567,867.632,479,547,947.46
  营业收入1,836,563,644.13797,791,349.653,695,567,867.632,479,547,947.46
二、营业总成本1,279,195,984.7608,608,067.392,481,201,979.551,721,216,914.12
  营业成本203,143,447.5884,135,622.69259,990,596.78184,529,708.94
  税金及附加23,572,839.6310,147,658.6719,964,915.1312,713,333.14
  销售费用668,309,988.2328,374,104.331,451,400,170.591,009,177,664.4
  管理费用186,072,149.4292,126,614363,909,982.98237,841,939.56
  研发费用196,797,734.993,643,656.62388,025,752.66279,335,347.75
  财务费用1,299,824.97180,411.08-2,089,438.59-2,381,079.67
  其中:利息费用2,443,097.52686,786.071,424,517.72764,381.47
  其中:利息收入2,194,075.75904,206.224,042,479.943,388,066.3
三、其他经营收益
  加:公允价值变动收益509,982.193,890.423,448,015.831,069,749.2
  加:投资收益2,298,419.11,658,683.696,599,263.412,619,663.12
  资产处置收益1,660,577.95626,708.78-718,026.1314,474.43
  信用减值损失(新)-276,133.06581,909-60,363.6695,990.26
  其他收益9,183,118.046,579,86427,008,206.2619,255,943.07
四、营业利润570,743,623.65198,634,338.151,250,642,983.79781,386,853.42
  加:营业外收入348,075.84142,855.121,157,219.52744,457.94
  减:营业外支出41,604,279.8719,737,063.7476,425,422.2651,133,598.75
五、利润总额529,487,419.62179,040,129.531,175,374,781.05730,997,712.61
  减:所得税费用52,960,473.6114,545,654.32144,138,528.4764,873,930.74
六、净利润476,526,946.01164,494,475.211,031,236,252.58666,123,781.87
(一)按经营持续性分类
  持续经营净利润476,526,946.01164,494,475.211,031,236,252.58666,123,781.87
(二)按所有权归属分类
  归属于母公司股东的净利润476,526,946.01164,494,475.211,031,236,252.58666,123,781.87
  扣除非经常损益后的净利润488,115,653.17165,332,467.091,062,128,487.04673,034,942.06
七、每股收益
  (一)基本每股收益1.170.42.531.64
  (二)稀释每股收益1.160.42.521.64
八、其他综合收益----81,743.32
  归属于母公司股东的其他综合收益----81,743.32
九、综合收益总额476,526,946.01164,494,475.211,031,236,252.58666,042,038.55
  归属于母公司股东的综合收益总额476,526,946.01164,494,475.211,031,236,252.58666,042,038.55
公告日期2026-08-192026-04-292026-03-272025-10-23
审计意见(境内)标准无保留意见
TOP↑